|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.09.25 - 09:09
|
Karolinska Development′s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01 (GlobeNewswire EN)
|
|
|
STOCKHOLM, SWEDEN September 16, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed enrollment in the phase 2a part of its clinical study GOAL-HF1. The ongoing study evaluates AnaCardio's drug candidate AC01 in patients with heart failure and reduced ejection fraction, with results expected by the end of the year. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure. The company's lead asset, AC01, is currently being evaluated in a clinical phase 1b/2a study, GOAL-HF1, in patients with heart failure and reduced ejection fraction (HFrEF)....
|
|
|
|
|
|
|
|
|
16.09.25 - 09:00
|
Virtune Strengthens European Expansion with Appointment of a Country Manager for Germany (GlobeNewswire EN)
|
|
|
Stockholm, September 16th, 2025 - Virtune, a leading and Swedish regulated crypto asset manager, is proud to announce the appointment of Benedict von Lucke as Country Manager for Germany. This strategic appointment marks an important step in Virtune's continued expansion across Europe and reinforces the company's commitment to making crypto investments accessible, secure, and transparent for both institutional and retail investors....
|
|
|
|
|
|
|
|
|
|
|
|
|
16.09.25 - 08:03
|
NBPE - Transaction in Own Shares (GlobeNewswire EN)
|
|
|
THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
